The Roles of Biomarker Testing and HRCT in IPF and PPF
Paul Noble, MD, discusses the roles of biomarker testing and HRCT in IPF and PPF.
EP: 1.Symptoms, Manifestations and Mortality Rate of IPF
EP: 2.How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF
EP: 3.Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis
EP: 4.Critical Early Diagnoses and Acute Exacerbations in IPF and PPF
EP: 5.Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis
EP: 6.Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis
EP: 7.Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis
Now Viewing
EP: 8.The Roles of Biomarker Testing and HRCT in IPF and PPF
EP: 9.Unmet Needs and the Role of AI in Earlier Disease Detection
EP: 10.Adverse Events Associated with Anti-Fibrotic Therapies
EP: 11.Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis
Video content above is prompted by the following:
- What’s the role of biomarker testing in IPF and PPF and can it be used to differentiate IPF and PPF from other diseases?
- What’s the role of HRCT in identifying patients with IPF or PPF and what’s commonly seen on histopathology?
Recent Videos
Related Content
Value-Based Decision-Making in Metastatic Breast Cancer
September 16th 2021Article
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
